Raya Leibowitz

Shamir, Z 70300, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Prognostic immunological implications of OX40L expression in the tumor microenvironment of melanoma.

Prognostic immunological implications of OX40L expression in the tumor microenvironment of melanoma.

Journal: Frontiers in immunology
Published: November 13, 2025

Mir-16 Decreases the Expression of VTI1B and SMPD1, Genes Involved in Membrane-Protein Trafficking in Melanoma.

Mir-16 Decreases the Expression of VTI1B and SMPD1, Genes Involved in Membrane-Protein Trafficking in Melanoma.

Journal: Cancers
Published: May 24, 2025

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications.

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications.

Journal: Journal for immunotherapy of cancer
Published: May 05, 2025

An urgent call for the cessation of hostilities in the Middle East.

An urgent call for the cessation of hostilities in the Middle East.

Journal: Lancet (London, England)
Published: March 19, 2025

Prolonged response to PIK3CA inhibition in an advanced hormone-positive breast cancer patient with 3 mutations in the alpha subunit of PI-3 kinase.

Prolonged response to PIK3CA inhibition in an advanced hormone-positive breast cancer patient with 3 mutations in the alpha subunit of PI-3 kinase.

Journal: The oncologist
Published: December 25, 2024

Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.

Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.

Journal: JCO precision oncology
Published: March 21, 2024

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.

Journal: Frontiers in immunology
Published: January 02, 2024

An urgent call for the immediate release of Israeli hostages.

An urgent call for the immediate release of Israeli hostages.

Journal: Lancet (London, England)
Published: October 10, 2023

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 26, 2023

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection.

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection.

Journal: Biosensors
Published: April 14, 2023

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Journal: European urology
Published: October 24, 2022

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

Journal: BMC cancer
Published: August 19, 2022
Showing 1-12 of 29

Last Updated: 09/26/2026